Guo Zun Hu

Mr. Guo Zun Hu

Weifang Medical University, Weifang, Shandong, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
GHGuo Zun Hu
Guo Zun Hu
SWShuang Wen
Shuang Wen
姿霍姿君 霍
姿君 霍
QWQing Wang
Qing Wang
JZJiantao Zhao
Jiantao Zhao
Shuanhu ZhouShuanhu Zhou
Shuanhu Zhou
Osteosarcoma (OS) is a highly malignant tumor occurring in bone tissue with a high propensity to metastasize, and its underlying mechanisms remain largely elusive. The OS prognosis is poor, and improving the survival of OS patients remains a challenge. Current treatment methods such as surgical approaches, chemotherapeutic drugs, and immunotherapeutic drugs remain ineffective. As research progresses, targeted therapy is gradually becoming irreplaceable. In this review, several treatment modalities for osteosarcoma, such as surgery, chemotherapy, and immunotherapy, are briefly described, followed by a discussion of targeted therapy, the important targets, and new technologies for osteosarcoma treatment.